Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA.
Chihara D, et al. Among authors: nastoupil lj.
Br J Haematol. 2017 Nov;179(3):503-506. doi: 10.1111/bjh.14226. Epub 2016 Jul 5.
Br J Haematol. 2017.
PMID: 27378601
Free PMC article.
No abstract available.